Real Time Touch

new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)

Real Time Touch

Lixte Biotechnology Inc patents

Recent patent applications related to Lixte Biotechnology Inc. Lixte Biotechnology Inc is listed as an Agent/Assignee. Note: Lixte Biotechnology Inc may have other listings under different names/spellings. We're not affiliated with Lixte Biotechnology Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "L" | Lixte Biotechnology Inc-related inventors

Oxabicycloheptanes and oxabicycloheptenes, their preparation and use

which may be used for the treatment of tumors.... Lixte Biotechnology Inc

Protein phosphatase 2a inhibitors for treating myelodysplastic syndromes

Disclosed are methods for treating a myelodysplastic syndrome (MDS) in a subject that involves administering to the subject a therapeutically effective amount of a protein phosphatase 2A (PP2A) inhibitor.... Lixte Biotechnology Inc

Process of synthesizing 3-(4-methylpiperazine-1-carbonyl)-7-oxabicyclo[2.2.1] heptane-2-carboxylic acid

wherein the first organic solvent is a substituted benzene.... Lixte Biotechnology Inc

Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase

Disclosed herein are methods of inhibiting proliferation of a cancer cell or inducing apoptosis of a cancer cell, which does not overexpress N—CoR. Also disclosed herein are methods of inhibiting proliferation or inducing apoptosis of a cancer cell that overexpresses TCTP and methods for determining whether a compound is effective... Lixte Biotechnology Inc

Sanguinarine analog pp2c inhibitors for cancer treatment

Sanguinarine analogs as PP2C inhibitors are disclosed for the treatment of various cancers, as well as methods of synthesizing such analogs.... Lixte Biotechnology Inc

Oxabicycloheptanes and oxabicycloheptenes for the treatment of ovarian cancer

A method of treating ovarian cancer in a subject afflicted therewith comprising administering to the subject an effective amount of an anti-cancer agent and an effective amount of a compound having the structure:... Lixte Biotechnology Inc

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009


This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. is not affiliated or associated with Lixte Biotechnology Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Lixte Biotechnology Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by